At Novadiscovery, a start-up/company specialized in in silico drug-efficiency models, one of their main challenge approaching pharmaceutical companies is to convince them of the power of in silico for such sensitive tasks as clinical trials. I was therefore in charge of gathering from the last 20 years literature, proofs of concepts of in silico helping and accelerating the development of drug design and development.